Clik here to view.
Analysts hike Cangene price targets
Versant Partners raised its 12-month price target on Cangene (TSX:CNJ) to $11 from $10 after the drug maker’s fiscal 2009 profit blew through analysts’ forecasts. On Thursday, Winnipeg-based Cangene...
View ArticleClik here to view.
Cangene to begin distributing WinRho in the U.S.
Cangene (TSX:CNJ) will assume the U.S. distribution of its WinRho SDF on June 1, 2010 from Baxter Healthcare, which had been selling the immune globulin IV product since March, 2005. “This move is in...
View ArticleClik here to view.
Cangene to leverage sales and marketing for acquisitions
Cangene (TSX:CNJ) hopes to parlay its new focus on sales and marketing as a stepping stone to acquire products from Big Pharma. “We’ve always been profitable, have money in the bank and have been...
View ArticleClik here to view.
Cangene taps Sedor as CEO
Cangene (TSX:CNJ) has named John Sedor as president and CEO, effective Sept. 12, replacing Dr. John Langstaff, who stepped down last January to pursue personal interests. CFO Michael Graham, who has...
View ArticleClik here to view.
Cangene in research pact for Alzheimer’s
Cangene (TSX:CNJ) has signed a collaborative research agreement with the University of British Columbia to develop the work of Dr. Neil Cashman, scientific director of PrioNet Canada and Canada...
View Article
